190 related articles for article (PubMed ID: 27651294)
1. Thermodynamic properties of leukotriene A
Wittmann SK; Kalinowsky L; Kramer JS; Bloecher R; Knapp S; Steinhilber D; Pogoryelov D; Proschak E; Heering J
Bioorg Med Chem; 2016 Nov; 24(21):5243-5248. PubMed ID: 27651294
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.
Numao S; Hasler F; Laguerre C; Srinivas H; Wack N; Jäger P; Schmid A; Osmont A; Röthlisberger P; Houguenade J; Bergsdorf C; Dawson J; Carte N; Hofmann A; Markert C; Hardaker L; Billich A; Wolf RM; Penno CA; Bollbuck B; Miltz W; Röhn TA
Sci Rep; 2017 Oct; 7(1):13591. PubMed ID: 29051536
[TBL] [Abstract][Full Text] [Related]
3. Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.
Appiah-Kubi P; Soliman M
Cell Biochem Biophys; 2017 Mar; 75(1):35-48. PubMed ID: 27914004
[TBL] [Abstract][Full Text] [Related]
4. Dual anti-inflammatory and selective inhibition mechanism of leukotriene A4 hydrolase/aminopeptidase: insights from comparative molecular dynamics and binding free energy analyses.
Appiah-Kubi P; Soliman ME
J Biomol Struct Dyn; 2016 Nov; 34(11):2418-33. PubMed ID: 26555301
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore-based virtual screening and Bayesian model for the identification of potential human leukotriene A4 hydrolase inhibitors.
Thangapandian S; John S; Sakkiah S; Lee KW
Eur J Med Chem; 2011 May; 46(5):1593-603. PubMed ID: 21377770
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, docking, cytotoxicity, and LTA
El-Naggar MH; Mira A; Abdel Bar FM; Shimizu K; Amer MM; Badria FA
Bioorg Med Chem; 2017 Feb; 25(3):1277-1285. PubMed ID: 28065501
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds.
Sandanayaka V; Mamat B; Bhagat N; Bedell L; Halldorsdottir G; Sigthorsdottir H; Andrésson T; Kiselyov A; Gurney M; Singh J
Bioorg Med Chem Lett; 2010 May; 20(9):2851-4. PubMed ID: 20371179
[TBL] [Abstract][Full Text] [Related]
8. Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.
Audat SA; Al-Shar'i NA; Al-Oudat BA; Bryant-Friedrich A; Bedi MF; Zayed AL; Al-Balas QA
Molecules; 2020 Jun; 25(12):. PubMed ID: 32580506
[TBL] [Abstract][Full Text] [Related]
9. Development of selective tight-binding inhibitors of leukotriene A4 hydrolase.
Yuan W; Munoz B; Wong CH; Haeggström JZ; Wetterholm A; Samuelsson B
J Med Chem; 1993 Jan; 36(2):211-20. PubMed ID: 8423594
[TBL] [Abstract][Full Text] [Related]
10. Classification and QSAR models of leukotriene A4 hydrolase (LTA4H) inhibitors by machine learning methods.
Qin R; Wang H; Yan A
SAR QSAR Environ Res; 2021 May; 32(5):411-431. PubMed ID: 33896285
[TBL] [Abstract][Full Text] [Related]
11. A sensitive fluorigenic substrate for selective in vitro and in vivo assay of leukotriene A4 hydrolase activity.
Poras H; Duquesnoy S; Fournié-Zaluski MC; Ratinaud-Giraud C; Roques BP; Ouimet T
Anal Biochem; 2013 Oct; 441(2):152-61. PubMed ID: 23851339
[TBL] [Abstract][Full Text] [Related]
12. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.
Davies DR; Mamat B; Magnusson OT; Christensen J; Haraldsson MH; Mishra R; Pease B; Hansen E; Singh J; Zembower D; Kim H; Kiselyov AS; Burgin AB; Gurney ME; Stewart LJ
J Med Chem; 2009 Aug; 52(15):4694-715. PubMed ID: 19618939
[TBL] [Abstract][Full Text] [Related]
13. PENG: a neural gas-based approach for pharmacophore elucidation. method design, validation, and virtual screening for novel ligands of LTA4H.
Moser D; Wittmann SK; Kramer J; Blöcher R; Achenbach J; Pogoryelov D; Proschak E
J Chem Inf Model; 2015 Feb; 55(2):284-93. PubMed ID: 25625859
[TBL] [Abstract][Full Text] [Related]
14. The development of novel LTA
Low CM; Akthar S; Patel DF; Löser S; Wong CT; Jackson PL; Blalock JE; Hare SA; Lloyd CM; Snelgrove RJ
Sci Rep; 2017 Mar; 7():44449. PubMed ID: 28303931
[TBL] [Abstract][Full Text] [Related]
15. Capturing LTA
Stsiapanava A; Samuelsson B; Haeggström JZ
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9689-9694. PubMed ID: 28827365
[TBL] [Abstract][Full Text] [Related]
16. Binding of Pro-Gly-Pro at the active site of leukotriene A4 hydrolase/aminopeptidase and development of an epoxide hydrolase selective inhibitor.
Stsiapanava A; Olsson U; Wan M; Kleinschmidt T; Rutishauser D; Zubarev RA; Samuelsson B; Rinaldo-Matthis A; Haeggström JZ
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4227-32. PubMed ID: 24591641
[TBL] [Abstract][Full Text] [Related]
17. Leukotriene A4 hydrolase as a target for cancer prevention and therapy.
Chen X; Wang S; Wu N; Yang CS
Curr Cancer Drug Targets; 2004 May; 4(3):267-83. PubMed ID: 15134534
[TBL] [Abstract][Full Text] [Related]
18. Overview of recent drug discovery approaches for new generation leukotriene A4 hydrolase inhibitors.
Calışkan B; Banoglu E
Expert Opin Drug Discov; 2013 Jan; 8(1):49-63. PubMed ID: 23095029
[TBL] [Abstract][Full Text] [Related]
19. Effect of alpha lipoic acid on leukotriene A
Torres MJ; Fierro A; Pessoa-Mahana CD; Romero-Parra J; Cabrera G; Faúndez M
Eur J Pharmacol; 2017 Mar; 799():41-47. PubMed ID: 28132911
[TBL] [Abstract][Full Text] [Related]
20. Leukotriene A4 hydrolase: identification of a common carboxylate recognition site for the epoxide hydrolase and aminopeptidase substrates.
Rudberg PC; Tholander F; Andberg M; Thunnissen MM; Haeggström JZ
J Biol Chem; 2004 Jun; 279(26):27376-82. PubMed ID: 15078870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
